← Back

ROADSTER 2 Early Outcomes

Early Outcomes in the ROADSTER 2 Study of Transcarotid Artery Revascularization in Patients With Significant Carotid Artery Disease

Share Share Copied! Compare

Year of Publication: 2020

Authors: Vikram S. Kashyap, Peter A. Schneider, Mazin Foteh, ..., Timothy Oskin

Journal: Stroke

Citation: Stroke. 2020;51:2620–2629

Link: https://doi.org/10.1161/STROKEAHA.120.030550

PDF: https://www.ahajournals.org/doi/epub/10....EAHA.120.030550

Clinical Question

What is the safety and efficacy of transcarotid artery revascularization (TCAR) performed by a broad group of physicians with variable TCAR experience using the ENROUTE Transcarotid Stent and Neuroprotection System?

Bottom Line

TCAR with the ENROUTE system demonstrates excellent early outcomes with high technical success (99.7%) and low stroke (0.6% per-protocol) and death rates (0.2% per-protocol) in high-risk patients, achieved by a majority of operators new to this technology.

        Major Points
        ROADSTER 2 is a prospective, open-label, single-arm, multicenter post-approval registry
692 patients enrolled at 43 sites; 632 in per-protocol analysis
81.2% of operators were TCAR naïve before study initiation
26% had neurological symptoms; all patients had high-risk factors for CEA
Technical success: 99.7% in both ITT and per-protocol populations
Per-protocol outcomes: 0.6% stroke, 0.2% death, 0.9% MI
ITT outcomes: 1.9% stroke, 0.4% death, 0.9% MI
Composite 30-day stroke/death rate: 0.8% (per-protocol), 2.3% (ITT)
Procedural success rate: 97.9% (per-protocol), 96.5% (ITT)
Protocol adherence critical for optimal outcomes

      

Design

Study Type: Prospective, open-label, single-arm, multicenter, post-approval registry

Randomization:

Blinding: Open-label design

Enrollment Period: 2015 - 2019

Follow-up Duration: 30 days

Centers: 43

Countries: United States, European Union

Sample Size: 632

Analysis: Intention-to-treat (ITT, n=692) and per-protocol (PP, n=632) populations analyzed using descriptive statistics

Inclusion Criteria

High risk for complications from carotid endarterectomy
Symptomatic stenosis ≥50% with stroke, TIA, or amaurosis fugax ≤180 days
Asymptomatic stenosis ≥80% without neurological symptoms ≤180 days
At least one clinical or anatomic high-risk criteria for CEA
Age ≥18 years
Signed informed consent
At least 5 cm of normal CCA below lesion for safe sheath placement

Exclusion Criteria

Alternative source of cerebral embolus (atrial fibrillation, heart valve)
Intracranial hemorrhage within 12 months
Evolving stroke or severe dementia
Major cardiovascular surgery within 30 days
Myocardial infarction within 72 hours
Carotid thrombus, occlusion, or string sign
Inflow disease or previous intervention in proximal ipsilateral carotid
Severe disease in common carotid artery
Entry site <5 cm to bifurcation
Open neck stoma

Baseline Characteristics

Characteristic	Control	Active
Total ITT Population		692 patients
Total Per-Protocol		632 patients
Male		67.8% (ITT), 67.7% (PP)
Age ≥80		21.1% (ITT), 21.2% (PP)
Hypertension		90.8% (ITT), 90.3% (PP)
Hyperlipidemia		86.3% (ITT), 85.8% (PP)
Diabetes		36.0% (ITT), 35.0% (PP)
Smoking History		77.7% (ITT), 77.8% (PP)
Previous MI		20.8% (ITT), 20.6% (PP)
Neurological Symptoms		26.0% (ITT), 26.3% (PP)
TIA/Stroke		16.0% (ITT), 16.1% (PP)
Age >75 years		42.1% (ITT), 41.8% (PP)
Anatomic Risk Factors Only		43.6% (ITT), 43.5% (PP)
Physiologic Risk Factors Only		31.8% (ITT), 31.8% (PP)
Both Risk Factors		24.6% (ITT), 24.7% (PP)

Arms

Field	TCAR with ENROUTE System
Intervention	Transcarotid artery revascularization using ENROUTE Transcarotid Stent and Neuroprotection System with reversal of flow cerebral protection
Duration	Single procedure with 30-day follow-up

Outcomes

Outcome	Type	Intervention
Procedural success (technical success plus absence of stroke, MI, or death within 30 days)	Primary	97.9% (PP), 96.5% (ITT)
Technical success	Secondary	99.7% (both ITT and PP)
Stroke at 30 days	Secondary	0.6% (PP), 1.9% (ITT)
Death at 30 days	Secondary	0.2% (PP), 0.4% (ITT)
Myocardial infarction at 30 days	Secondary	0.9% (both PP and ITT)
Composite stroke/death	Secondary	0.8% (PP), 2.3% (ITT)
Composite stroke/death/MI	Secondary	1.7% (PP), 3.2% (ITT)
Cranial nerve injury	Adverse	1.3% (PP), 1.4% (ITT)

Subgroup Analysis

Symptomatic patients (PP): 0.6% stroke, 0% death, 0.6% MI. Asymptomatic patients (PP): 0.6% stroke, 0.2% death, 1.1% MI. Protocol adherence crucial for optimal outcomes.

Criticisms

Single-arm design without randomized control group
60 patients had major protocol violations (medication non-compliance)
Only early 30-day outcomes reported
Learning curve effects possible despite training
Selection bias inherent in registry design
No direct comparison to CEA in same time period
Majority of operators were TCAR naïve, limiting generalizability

Funding

Post-approval study was a condition of FDA approval for ENROUTE Stent

Based on: ROADSTER 2 Early Outcomes (Stroke, 2020)